Summary Precision oncology has expanded rapidly across the Asia–Pacific region, yet implementation remains heterogeneous because of differences in health-system organisation, reimbursement, molecular tumour board infrastructure, workforce capacity, and data integration. This structured narrative review with expert cons...
H. Bando, H. Okayama, Yoon Jung Chang et al.· The Lancet Regional Health -...· 1 citation
Background Aging is a major nonmodifiable risk factor for cancer, yet age-associated genomic instability, inflammatory activation, and tumor microenvironment interactions remain poorly characterized. Patients and methods The primary genomic cohort comprised 153 treatment-naïve patients with six cancer types, stratified...
S. Yajima, Y. Tsukada, Y. Sota et al.· Immuno-Oncology Technology· 0 citations
Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenge...
S. Kobayashi, T. Hashimoto, H. Bando et al.· Cancer Cell· 0 citations
Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulating tumor DNA (ctDNA) after definitive treatment predicts recurrence, and emerging molec...
Yoshiaki Nakamura, K. Namikawa, D. Ogata et al.· Cancer Research Communicatio...· 0 citations
Cancer genomic data sharing is a core pillar of precision oncology, underpinning reproducibility, scalability, and equity. The ability to discover, access, integrate, interpret, and reuse cancer 'omics data is a key determinant of precision oncology's value and benefit at scale. This work has been conducted as part of...
D. Torrents, Oliver Hofmann, K. Cranston et al.· EBioMedicine· 1 citation
The Commission developed a value-based resource-stratified implementation framework, a system-readiness assessment tool, a precision oncology workforce competency-based framework, a precision oncology monitoring and evaluation framework, and principles for responsible data sharing and health-system learning.
R. Casolino, J. Mateo, E. D. de Vries et al.· The Lancet Oncology· 11 citations
Results show that post-treatment circulating tumor RAS and BRAF MT dynamics may serve as useful prognostic indicators, particularly with regard to BRAF MT.
H. Osumi, E. Shinozaki, Yoshiaki Nakamura et al.· iScience· 0 citations
ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.
M. Raeisi, T. André, Q. Shi et al.· Journal of the National Canc...· 0 citations
A purpose-oriented framework clarifying the levels of relevance and reliability required according to specific regulatory objectives is proposed, and practical recommendations for generating regulatory-grade RWE that meaningfully informs regulatory decision-making while complementing conventional clinical trials are pr...
Yasutoshi Sakamoto, H. Bando, Yoshihiro Aoyagi et al.· International Journal of Cli...· 0 citations
It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...
T. Hashimoto, T. Shibuki, T. Fujisawa et al.· International Journal of Cli...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
